BioXcel Therapeutics Secures $14 Million Through Direct Stock Offering
BioXcel Therapeutics, Inc. (the "Company") (Nasdaq: BTAI), a pioneering biopharmaceutical firm harnessing artificial intelligence to innovate treatments in neuroscience, has made a significant move by entering into a securities purchase agreement with select institutional investors. This agreement revolves around a registered direct offering involving 4,000,000 shares of its common stock, which is valued at $0.001 per share.
Details of the Offering
The registered direct offering sets a combined price of $3.50 per share. This initiative is projected to yield approximately $14 million for the Company before factoring in fees for the placement agent and other related expenses. Investors will also receive accompanying warrants, allowing them to purchase an additional 4,000,000 shares at an exercise price of $4.20 per share. This warrants investors significant flexibility as they can exercise these options after issuance.
Exclusive Placement Agent
To facilitate this offering, the Company has partnered with Rodman & Renshaw LLC, which is serving as the exclusive placement agent. The collaboration is expected to bring substantial advantages to both parties, enhancing market confidence and expanding investor reach.
Utilization of Proceeds
With the closing expected soon, the Company plans to channel the proceeds from this offering into working capital and various corporate purposes. This strategic allocation reinforces BioXcel’s commitment to advancing its operational efforts and achieving its corporate goals.
Registration Compliance
The securities involved in this offering were made available via a shelf registration statement, which was previously filed with the appropriate regulatory bodies and has received approval. The move exemplifies the Company's adherence to legal and regulatory standards in its capital-raising endeavors.
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is at the forefront of biopharmaceutical development, focusing on innovative applications of artificial intelligence to create transformative medicines in the field of neuroscience. Its dedicated subsidiary, OnkosXcel Therapeutics, LLC, zeros in on developing therapies specifically for immuno-oncology.
The Company employs a unique drug re-innovation strategy. This approach combines existing approved medications with advanced data analytics and proprietary algorithms. The goal is to identify new therapeutic possibilities that can significantly benefit patients and address unmet medical needs.
Continuous Growth and Future Directions
BioXcel is poised for growth as it continues to explore and validate new therapeutic avenues. By leveraging artificial intelligence and data-driven insights, the company aims to bring forth innovations that could redefine treatment paradigms in neuroscience and beyond.
Frequently Asked Questions
What is BioXcel Therapeutics known for?
BioXcel Therapeutics is recognized for utilizing artificial intelligence to develop groundbreaking treatments in neuroscience and immuno-oncology.
How much capital did BioXcel raise in the recent offering?
The company raised approximately $14 million through its recent securities purchase agreement.
What are the exercise terms of the accompanying warrants?
The accompanying warrants can be exercised at any time after the date of issuance at an exercise price of $4.20 per share of common stock.
Who is the exclusive placement agent for this offering?
Rodman & Renshaw LLC is acting as the exclusive placement agent for the direct stock offering.
What will the proceeds from the offering be used for?
The net proceeds from the offering are intended for working capital and general corporate purposes, supporting the Company’s growth initiatives.
